

05-30-2001

ER SHEET



LY

101733900

To the Honorable Commissioner of Patents and Trademarks

Send original documents or copy thereof.

## 1. Name of conveying party(ies):

Medco Research, Inc.

5.22.01

Additional name(s) of conveying party(ies) attached? ☐ Yes ☐ No

## 3. Nature of conveyance:

☐ Assignment☐ Merger☐ Security Agreement☒ Change of Name☐ Other

Effective Date: November 1, 2000

## 2. Name and address of receiving party(ies):

Name: King Pharmaceuticals Research and Development, Inc.

Internal Address:

22

Street Address: 7001 Weston Parkway, Suite 300

City: Cary State: NC ZIP: 27513

Additional name(s) & address(es) attached? ☐ Yes ☐ No

## 4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

See Schedule A

B. Patent No.(s)

See Schedule A

09379300

Additional numbers attached? ☐ Yes ☐ No

## 5. Name and address of party to whom correspondence concerning document should be mailed:

Name: John K. Abokhair.

Internal Address:

Street Address: Roberts Abokhair &amp; Mardula

11800 Sunrise Valley Drive, Suite 1000

City: Reston State: VA ZIP: 20191

## 6. Total number of applications and patents involved: 11

7. Total fee (37 CFR 3.41): \$ 480.00

☒ Enclosed☐ Authorized to be charged to deposit account

## 8. Deposit account number:

18/1579

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

## 9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

John K. Abokhair, Esq.

Name of Person Signing

Signature

5/22/01

Date

Total number of pages including cover sheet:

## Schedule A

<u>Name</u>	<u>Serial/Patent No.</u>	<u>File/Issue Date</u>
Adenosine A3 Receptor Modulators	09/379,300	08/23/99
Allosteric Adenosine Receptor Modulators	09/156,077	09/17/98
Allosteric Adenosine Receptor Modulators	6,177,444	01/23/01
The Use of Adenosine A3 Receptor Antagonists To Inhibit Tumor Growth	09/377,271	08/19/99
Novel Method of Myocardial Imaging	5,070,877	12/10/91
Allosteric Adenosine Receptor Modulators	6,194,449	02/27/01
Method of Minimizing Damage to Heart Tissue During Cardiac Surgery and Cardiac Transplantation	09/300,128	04/27/99
Diagnostic Uses of 2-Substituted Adenosine Carboxamides	09/440,330	11/15/99
N-6 Substituted-Adenosine-5-Uronamides as Adenosine Receptor Modulators	6,048,865	04/11/00
Thiophenes Useful for Modulating the Adenosine Receptor	5,939,432	08/17/99
Adenosine A3 Receptor Modulators	09/154,435	09/16/98
Method for Treating Hyper-Excited Sensory Nerve Functions in Humans	09/654,994	09/05/00

In the United States Patent and Trademark Office

In re Application of: King Pharmaceuticals Research and  
Development, Inc.

Serial No.: See Schedule A  
Filed: See Schedule A  
For: See Schedule A

Group Art Unit:  
Examiner:

Commissioner for Patents  
Box Assignment  
Washington, D.C. 20231

Notice of Change of Corporate Name for Assignee

Dear Sir:

Applicant wishes to advise that its corporate name has been changed  
(Amendment attached), and requests that such change be recorded by the Patent  
and Trademark Office.

The new name, which is to be used in all future correspondence in this  
application, is:


King Pharmaceuticals Research and Development, Inc.  
7001 Weston Parkway, Suite 300  
Cary, NC 27513

A recordation sheet and check in the amount of \$480.00 is enclosed for  
filing of the corporate name change for the above trademark applications.

Please continue to direct all correspondence and telephone  
calls concerning these applications to applicant's attorney, Jon L. Roberts,  
at:

ROBERTS ABOKHAIR & MARDULA  
11800 Sunrise Valley Drive  
Suite 1000  
Reston, VA 20191-5302  
Phone: (703) 391-2900  
Fax: (703) 391-2901

Respectfully,




Attorney for Applicant  
John K. Abokhair, Esq.  
Registration No. 30,537  
Roberts Abokhair & Mardula, LLC  
11800 Sunrise Valley Drive, Suite 1000  
Reston, VA 20191-5302  
(703) 391-2900

State of Delaware  
Office of the Secretary of State

---

PAGE 1

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "MEDCO RESEARCH, INC.", CHANGING ITS NAME FROM "MEDCO RESEARCH, INC." TO "KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC.", FILED IN THIS OFFICE ON THE FIRST DAY OF NOVEMBER, A.D. 2000, AT 3 O'CLOCK P.M.



*Harriet Smith Windsor*  
Harriet Smith Windsor, Secretary of State

2417050

AUTHENTICATION: 0966079

010061581

DATE: 02-09-01

PATENT  
REEL: 011828 FRAME: 0671

CERTIFICATE OF AMENDMENT  
OF  
CERTIFICATE OF INCORPORATION  
OF  
MEDCO RESEARCH, INC.

MEDCO RESEARCH, INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware,

DOES HEREBY CERTIFY:

FIRST: That the Board of Directors of said corporation, by the unanimous written consent of its members, filed with the minutes of the Board, adopted a resolution proposing and declaring advisable the following amendment to the Certificate of Incorporation of said corporation:

RESOLVED, that the Certificate of Incorporation of Medco Research, Inc. be amended by changing Article I thereof so that, as amended, said Article shall be and read as follows:

"The name of this corporation is King Pharmaceuticals Research and Development, Inc. (the "Corporation")."

SECOND: That in lieu of a meeting and vote of the stockholders, the stockholders have given unanimous written consent to said amendment in accordance with the provisions of Section 228 of the General Corporation Law of the State of Delaware.

THIRD: That the aforesaid amendment was duly adopted in accordance with the applicable provisions of Sections 242 and 228 of the General Corporation Law of the State of Delaware.

STATE OF DELAWARE  
SECRETARY OF STATE  
DIVISION OF CORPORATIONS  
FILED 03:00 PM 11/01/2000  
001550784 - 2417050

NOV-01-33 14:33

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: King Pharmaceuticals Research and  
Development, Inc.

Serial No.: See Schedule A  
Filed: See Schedule A

Group Art Unit:  
Examiner:

For: See Schedule A

Commissioner for Patents  
Box Assignment  
Washington D.C. 20231

Dear Sir:

Enclosed please find the following:

1. Change of Corporate Name for Applicant for See Schedule A;
2. Secretary's Certificate;
3. Certificate of Amendment;
4. Recordation sheet for corporate name change;
5. One check in the amount of \$480.00; and
6. Certificate of Express mailing.

The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 18-1579. The Commissioner is also authorized to charge Deposit Account No. 18-1579 for any future fees connected in any way to this application. Two copies of this letter are enclosed.

Respectfully submitted,



John K. Abokhair, Esq.  
Registration No. 30,537  
Roberts Abokhair & Mardula, LLC  
11800 Sunrise Valley Drive, Suite 1000  
Reston, VA 20191-5302  
(703) 391-2900

May 22, 2001

CERTIFICATE OF EXPRESS MAILING

Express Mail Mailing Label Number EL739320384US

Date of Deposit: May 22, 2001

I hereby certify that the request for change of corporate name of assignee for See Schedule A, Serial No. See Schedule A, Secretary's Certificate, Certificate of Amendment and one check in the amount of \$480.00 are being deposited with the United States Postal Service for "Express Mail" service under 37 C.F.R. § 1.10 on the date indicated above and are addressed to the Commissioner for Patents, Box Assignment, Washington, D.C. 20231.



John K. Abokhair, Esq.  
Registration No. 30,537  
Roberts Abokhair & Mardula, LLC  
11800 Sunrise Valley Drive, Suite 1000  
Reston, VA 20191-5302  
(703) 391-2900

May 22, 2001